Official Title
Prediction of Acute Heart or Kidney Injury With Cardiovascular-renal Biomarkers in Patients Hospitalised for Severe or Critical Covid-19 Infection
Brief Summary

The Nancy Cov-H-AKI: study is a prospective, non-randomized, monocenter study performed in patients hospitalised for either the severe or the critical form of Covid-19. The main objective of the Nancy Cov-H-AKI study is to evaluate the association of variations (from inclusion to 72H post-inclusion) of 5 blood-based cardio-vascular-renal biomarkers selected a priori, cardiac (NT-proBNP), coagulation (D-dimers), related to the renin angiotensin aldosterone system (ACE2) and renal (Penkid, and NGAL) with the appearance of acute kidney injury KDIGO grade 1 or higher OR cardiac injury in patients hospitalised for either the severe or the critical form of Covid-19

Detailed Description

Secondary objectives



Evaluate the association of the concentrations at inclusion AND of the variations (between

inclusion and 72H post-inclusion) of blood and urine cardiovascular-renal biomarkers of

interest (selected a priori: cardiac (NT-proBNP, (bio)-Adrenomedullin), coagulation

(D-dimers), linked to the renin angiotensin aldosterone system (renin, ACE2, Angiotensin 2),

inflammatory (ceramides), oxidative stress, and renal (PENKID, cystatin C) and renal

glomerulo-tubulopathy ( renal functional exploration in blood and urine, and AKI (blood

(NGAL, KIM-1) and urinary (IGFBP7-TIMP2)) biomarkers, AND WITHOUT a priori by an analysis of

184 blood protein biomarkers in connection with cardiovascular and inflammatory damage * )

with the appearance of:



1. AKI KDIGO grade 1 or higher or elevation of troponin >99th percentile in hospitalisation

(approach with AND without a priori)



2. AKI KDIGO grade 1 or higher



3. Elevation of troponin >99th percentile in hospitalisation



4. Elevated serum creatinine >30% in hospital



5. Chronic renal failure (eDFG <60 ml / min / 1.73m2) three months after discharge from

hospital



6. Cardiovascular events (stroke, myocardial infarction, hospitalization for heart failure,

cardiovascular death) and mortality in hospital and at three months after discharge from

hospital



7. Considering future exploratory analyses (biological collection of plasma, serum, saliva,

urine, viruses) (for example other OLINK panels) on the previous endpoints



- NGAL (Neutrophil Gelatinase Associated Lipocalin), Cystatin C, Kidney Injury

Molecule-1 (Kim-1), ACE-2, renin, Brain-type Natriuretic Peptide (BNP),

Adrenomedullin, FGF (fibroblast growth factor-23 are all included in the 2 Olink

panels "CVDII" (https://www.olink.com/products/cvd-ii-panel/: listing) and

"cardiometabolic" (https://www.olink.com/products/cardiometabolic-panel /)

Active, not recruiting
COVID 19

Procedure: Biological samples specific to research
Blood samples, saliva collection, and urine collection to carry out biomarker assays and for the constitution of a biological collection.
Patients hospitalized for Covid-19 infection

Procedure: Clinical examination
Clinical examination
Patients hospitalized for Covid-19 infection

Procedure: Telephone follow-up
Telephone follow-up at 3 months after discharge from hospital
Patients hospitalized for Covid-19 infection

Eligibility Criteria

Inclusion Criteria: - Patients over the age of 18, - Admission for less than 3 days in the medical service (or in intensive care) for proven serious form of Covid 19 infection (respiratory rate >30 / min, or desaturation in air ≤ 93%, or PaO2 / FiO2 ≤ 300mmHg) - OR Admission for less than 2 days in intensive care (or resuscitation intensive care) for critical form of Covid 19 (shock or respiratory failure). - GFR greater than 30 ml / min / 1.73m2. - Troponin

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Countries
France
Central Hospital, Nancy, France
NCT Number
MeSH Terms
Infection